Gilead, Cognizant

Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
Cognizant expands AI services for Gilead Sciences
Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee engagement,
Cognizant Expands Partnership With Gilead Sciences To Enhance Efficiency And AI Integration
Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Cognizant, Gilead expand relationship
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
stocknews13h
3 Biotech Stocks Revolutionizing Healthcare
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Business Wire2d
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Gilead Worker Accused of Sex Harassment Advances Defamation Suit
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
Zacks.com on MSN2d
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm ...